Randomized Trialhigh evidence
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
The New England journal of medicine·May 31, 2026·PMID 42223072
Why it mattersThis is the first phase 3 trial to show a substantial survival benefit with a RAS-targeted therapy in pancreatic cancer, where >90% of tumors harbor RAS mutations and current options are limited.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled